Titusville: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved CAPLYTA ...

The J&J antipsychotic drug Caplyta won FDA approval for depression, a broader indication that could help the medicine become ...

In short, actively seek out something to smile about—even if the smile feels forced. According to Allyson Pimentel of the ...

The expanded indication for the oral atypical antipsychotic now includes adjunctive use with antidepressants in adults with major depressive disorder.

Why hadn’t I been able to save my son? What biological mechanisms made him so relentlessly ill? Could more effective ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

Johnson & Johnson (JNJ) stock is in focus as the FDA further expands the labeling for its antipsychotic to treat adults with ...

Depression, anxiety, and PTSD are linked to early onset of Alzheimer’s disease, and greater psychiatric burden may further ...

Sun Pharmaceutical issued a voluntary recall of lisdexamfetamine dimesylate capsules, used for attention ...

The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive ...

Researchers say eye diseases, mood disorders, and certain proteins in the body could help predict dementia years before ...